RxDoctor Payments Data

Samip Patel, MD

Neurology · Annapolis, MDNPI 1932302551

Payments from drug & device makers

$10,083in general payments, 2019–2025

Across 491 payments — averaging $20.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$746
  • Livanova USA, Inc.$696
  • Pfizer$668
  • Biogen$541
  • Lilly USA, LLC$537
  • plus $6K from 54 others

What the payments were for

  • Speaking & faculty fees$631%
  • Travel & lodging$2783%
  • Food & beverage$9,73397%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)72$1,144
Novartis41$746
Livanova USA, Inc.5$696
Pfizer36$668
Biogen26$541
Lilly USA, LLC31$537
Teva Pharmaceuticals USA, Inc.26$496
Amgen(2 entities)23$488
Lundbeck LLC17$353
Grifols USA, LLC10$230
Eisai Inc.10$226
CSL Behring10$216
Genentech USA, Inc.8$206
Bristol Myers Squibb10$204
Takeda Pharmaceuticals U.S.A., Inc.8$182
Jazz Pharmaceuticals Inc.6$174
Neurelis, Inc.7$152
Sunovion Pharmaceuticals Inc.10$151
EMD Serono, Inc.7$149
Acadia Pharmaceuticals Inc9$148
Argenx US, Inc.5$142
Catalyst Pharmaceuticals, Inc.5$131
Amneal Pharmaceuticals LLC6$113
Sanofi6$113
Axsome Therapeutics, Inc.5$112
Sumitomo Pharma America, Inc.6$106
AstraZeneca(2 entities)6$105
UCB, Inc.4$95
Avanir Pharmaceuticals, Inc.5$93
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)5$91
Corcept Therapeutics4$84
Inspire Medical Systems, Inc.3$78
Actelion Pharmaceuticals US, Inc.3$76
Baxter Healthcare3$72
TG Therapeutics, Inc.3$67
Shire North American Group Inc4$66
Acorda Therapeutics, Inc3$63
Alnylam Pharmaceuticals Inc.4$60
Aucta Pharmaceuticals, Inc.4$57
Biohaven Pharmaceutical Holding Company Ltd.2$56
Sanofi-aventis U.S. LLC2$43
Averitas Pharma Inc.2$43
Johnson & Johnson2$40
Harmony Biosciences LLC1$33
Xeris Pharmaceuticals, Inc.2$32
Vanda Pharmaceuticals Inc.2$32
Neurocrine Biosciences, Inc.1$31
Greenwich Biosciences, Inc.2$31
Soleno Therapeutics, Inc.1$28
Regeneron Healthcare Solutions, Inc.2$26
Otsuka America Pharmaceutical, Inc.1$24
Kowa Pharmaceuticals America, Inc.2$22
Avadel CNS Pharmaceuticals, LLC1$21
Ultragenyx Pharmaceutical Inc.1$21
Avion Pharmaceuticals1$20
Kestra Medical Technology Services, Inc.1$19
Tandem Diabetes Care, Inc.1$18
Resmed Corp1$18
SK Life Science, Inc.1$16
Ipsen Biopharmaceuticals, Inc1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,083 in reported general payments places this provider in the 65th percentile of 442 neurology providers in Maryland.

See all neurology providers in Maryland

Medicare billing

Part B allowed, 2024
$189,013
Medicare patients
937
Services billed
1,269

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gamunex-CImmune Globul G/Gly/Iga Avg 4612$271,379
Tetrabenazine19$121,407
Kesimpta PenOfatumumab12$105,728
NuplazidPimavanserin Tartrate18$89,866
Nurtec OdtRimegepant Sulfate16$33,469
NuedextaDextromethorphan Hbr/Quinidine13$28,771
UbrelvyUbrogepant16$28,551
Emgality SyringeGalcanezumab-Gnlm13$25,837
BotoxOnabotulinumtoxina17$22,435
Aimovig AutoinjectorErenumab-Aooe30$21,777
FycompaPerampanel16$19,719
FingolimodFingolimod Hcl13$8,100
Lacosamide46$7,869
Levetiracetam130$5,462
Carbamazepine ErCarbamazepine35$5,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCGamunex-C$230$271,37912 claims
Acadia Pharmaceuticals IncNuplazid$148$89,86618 claims
AbbVieUbrelvy, Botox$1,144$50,98633 claims
PfizerNurtec Odt$668$33,46916 claims
Avanir Pharmaceuticals, Inc.Nuedexta$93$28,77113 claims
Eisai Inc.Fycompa$226$19,71916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 442 neurology providers in Maryland.

Other neurology in Annapolis

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →